Fedratinib

(Inrebic®)

Inrebic®

Drug updated on 11/14/2023

Dosage FormCapsule (oral: 100 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).

Product Monograph / Prescribing Information

Document TitleYearSource
Inrebic (fedratinib) Prescribing Information.2021Celgene Corporation, Summit, NJ

Systematic Reviews / Meta-Analyses